TheStreet upgraded shares of AngioDynamics (NASDAQ:ANGO) from a c rating to a b rating in a research note published on Wednesday morning, TheStreetRatingsTable reports.

ANGO has been the subject of a number of other reports. Zacks Investment Research raised Investar from a hold rating to a buy rating and set a $27.00 price target for the company in a research note on Tuesday, June 4th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Finally, BidaskClub raised Westport Fuel Systems from a hold rating to a buy rating in a research note on Friday. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. AngioDynamics presently has a consensus rating of Buy and an average target price of $21.50.

Shares of AngioDynamics stock opened at $21.68 on Wednesday. The company’s 50 day moving average price is $19.62. AngioDynamics has a 12 month low of $18.11 and a 12 month high of $25.48. The company has a market capitalization of $814.66 million, a price-to-earnings ratio of 26.69 and a beta of 0.69. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.70 and a current ratio of 4.30.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The firm had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. During the same period in the previous year, the company posted $0.20 earnings per share. AngioDynamics’s quarterly revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts predict that AngioDynamics will post 0.27 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans lifted its stake in shares of AngioDynamics by 2.2% in the 4th quarter. Thrivent Financial for Lutherans now owns 26,360 shares of the medical instruments supplier’s stock valued at $531,000 after purchasing an additional 579 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of AngioDynamics by 21.4% in the 4th quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 601 shares during the last quarter. Texas Permanent School Fund lifted its stake in shares of AngioDynamics by 3.8% in the 1st quarter. Texas Permanent School Fund now owns 25,215 shares of the medical instruments supplier’s stock valued at $576,000 after purchasing an additional 923 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of AngioDynamics by 100.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 1,100 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of AngioDynamics by 28.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 1,181 shares during the last quarter. 98.46% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: What Does a Sell-Side Analyst Rating Mean?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.